March 4, 2026 · Executive Brief

International HPV Awareness Day 2026

Make vaccination, screening, follow-up, and cancer prevention one stigma-free route.

Written byGreg WahlstromMBAHCMPresident and Chief Executive Officer, The Healthcare ExecutiveOctober 2026 27 min read

The 2026 leadership signal

HPV prevention fails when its parts operate separately.

HPV is common, often stigmatized, and linked to several cancers. Awareness must avoid blame while giving people clear, age-appropriate information about vaccination, screening, follow-up, and treatment.

Executives should look for missed opportunities across pediatrics, primary care, pharmacy, sexual health, dentistry, gynecology, and oncology rather than assigning prevention to one clinic.

Audit one eligible population from vaccination or screening opportunity through completion, result communication, and required follow-up.

Campaign reach

155+ partners

The 2026 International HPV Awareness Day campaign reported more than 155 partners.

Cervical cancer

660,000 cases

WHO estimated about 660,000 new cervical cancer cases worldwide in 2022; persistent high-risk HPV infection causes nearly all cervical cancers.

Prevention potential

More than 90%

CDC states that HPV vaccination can prevent more than 90% of cancers caused by HPV.

Figures are summarized from the authoritative sources linked below. Definitions and denominators should be read with each source.

Executive opening

HPV prevention is an operating system, not a single visit

HPV prevention depends on a chain of ordinary events. A clinician recommends the vaccine, a family agrees, a dose is given, the next dose is scheduled, and years later screening and follow-up catch what vaccination missed. Each link sits with a different team, and a break anywhere leaves a person unprotected. For executives, the question is which links their organization owns and how reliably each one holds. A campaign can raise interest for a day, but only owned handoffs turn that interest into completed doses and resolved results.

The gaps are large even in well-resourced systems. In the United States, only 47% of young adults aged 18 to 26 had initiated the HPV vaccine in 2022.^[2] At one large public university, 76.4% of students whose provider recommended the vaccine were vaccinated, compared with 16.7% of those without a recommendation.^[4] Recommendation quality is therefore a measurable operating variable, not a matter of individual style. It can be standardized, observed and improved like any other clinical process.

Delivery design matters as much as messaging. A comparative policy analysis of eight countries found that school-based delivery supported by nursing and school health workforces consistently achieved the highest and most equitable coverage.^[1] Across 84 low- and middle-income countries, only 9.8% had reached the global target of 90% complete vaccination among girls by age 15.^[9]

This brief adds the evidence base to the executive guidance above. It examines current evidence on coverage and recommendation, the continuum from first dose to screening follow-up, access, equity and stigma, the prevention workforce, and public communication. The aim is one accountable improvement in a prevention handoff that the organization can measure and own. Every figure below comes from a cited study, and the operating suggestions are executive guidance rather than clinical protocol.

Executive angle

This observance gives healthcare executives an opportunity to raise HPV vaccination and cervical screening completion by strengthening a prevention operating system built on consistent provider recommendation, school and community partnerships, reliable reminder-recall and owned follow-up of abnormal results.

Questions for the executive team

What share of eligible children, adolescents and young adults in our population have started and completed the HPV vaccine series, and where do they drop out?
How consistently do our clinicians, pharmacists and dental teams make a clear HPV vaccine recommendation, and how would we know?
Which C-suite leader and board committee own HPV vaccination and cervical screening completion, including abnormal result follow-up?
Do we partner with schools and community organizations on vaccination, consent and education, or do we rely on clinic visits alone?

How many patients with abnormal screening results lack a documented next step, and who reviews that list?
Do vaccination, screening and follow-up rates differ by age, language, geography, insurance, sexual orientation or gender identity?
Could self-collection extend cervical screening to people our current model does not reach?
What will we measure at 30, 60 and 90 days to show that one prevention handoff has become more reliable?

Current evidence

What the evidence shows about coverage, recommendation and delivery

Coverage builds slowly after programs begin, and it often stalls below targets. Across 43 European countries, population-weighted coverage among adolescent girls reached about 40% by year 2 of a national program and stabilized at 55–60% by year 5.^[7] Coverage exceeded 60% in most countries only by year 15.^[7] Lower public disagreement with vaccine safety and higher physician density were significant determinants, and school-based programs were associated with a faster increase.^[7] Coverage across the region remained uneven and below the 90% target, according to the authors.^[7]

The pattern holds in low- and middle-income settings. A scoping review of 84 countries with national programs found that school-based programs maintained more stable performance over time than health facility-based approaches.^[9] Nearly half had adopted single-dose schedules, a trend toward simpler delivery.^[9] The eight-country policy analysis reported that Rwanda achieved 98% coverage with a girls-only, donor-supported model.^[1] Its authors suggested that governance quality and community trust may outweigh policy design alone.^[1]

Acceptance does not guarantee uptake. A systematic review of 16 studies with 10,764 participants in Nigeria found vaccine acceptance ranging from 32.7% to 97.3%.^[11] Actual uptake remained low, at 1% to 15% in most studies.^[11] Limited knowledge and awareness were the most consistent determinants, alongside lack of provider recommendation, cost and limited availability.^[11] Fear of side effects and misconceptions about infertility or sexual behavior also appeared, as did parental approval and religious beliefs.^[11] The gap between intention and action is where operations matter most.

Recommendation is the operating lever that recurs across settings. In a caregiver survey in Tonga, trust in health workers was high (87.9%), yet only 41.5% of caregivers reported receiving a provider recommendation.^[10] Knowing that the vaccine was free was the strongest predictor of uptake (aOR 3.21).^[10] Trust that is never converted into a clear recommendation is a missed opportunity the system can see and fix. The authors called for improved provider recommendation practices and clearer communication about vaccine cost and purpose.^[10]

Screening evidence adds a second layer. In 4,648 women with abnormal screening results and a type 3 transformation zone, 3.1% had high-grade lesions despite a negative colposcopy.^[14] Risk varied by cytology, HPV genotype and age, which supports risk-based tracking of follow-up rather than one schedule for all.^[14] Among women with high-grade cytology, high-grade lesion risk was 32.5%-37.2% across HPV subgroups.^[14] The operational point is that abnormal results carry real risk until someone closes them.

Figure 1

Recommendation is the hinge between trust and protection

Percent of people or providers at a recommendation or vaccination step, as reported in each study. Values are copied from the cited studies [2], [4], [10], [13]; none is estimated.

Data note. These values come from different studies, populations and measures, so this is an indirect comparison; only the two university bars come from the same sample.

Limitation. Most values are self-reported; the university survey had about a 4% response rate, and the Tonga and dental samples are not representative of U.S. health systems.

Figure data (5 rows)

Figure 1 data: Recommendation is the hinge between trust and protection
Measure	Value	Population, setting and year as reported	Source
U.S. young adults who had initiated the HPV vaccine, 2022	47%	Adults aged 18 to 26 in the United States, as reported in a 2026 study background	[2]
Students vaccinated when a provider recommended it	76.4%	Students aged 18 to 26 at one New York State public university, surveyed March 2022	[4]
Students vaccinated without a provider recommendation	16.7%	Same university survey, March 2022	[4]
Caregivers who reported receiving a provider recommendation	41.5%	398 caregivers of girls aged 9 to 14 in Tonga, August 2025; trust in health workers was 87.9%	[10]
Dental hygienists who recommended the vaccine to patients	15%	Dental hygienists attending one regional continuing education course	[13]

A school nurse talks with a twelve-year-old boy and his mother before his vaccine, a capped syringe on a tray. — Illustrative image. Students whose provider recommended the HPV vaccine were far more likely to be vaccinated in one university survey.^[4]

Continuum of care

From first dose to series completion and result follow-up

The first dose is only the start of the prevention continuum. In a predominantly Hispanic U.S.-Mexico border county, a program tracking 1,787 participants found that young adults were less likely than those aged 9 to 17 to complete the series.^[15] Failure to contact was the most common barrier to completion, followed by scheduling concerns.^[15] The authors concluded that the barriers were predominantly structural, tied to access and quality of care.^[15]

That finding points directly at reminder-recall operations. If the most common reason a series goes unfinished is that the program could not reach the person, then contact data, outreach timing and channel choice become clinical quality issues. Each missed contact should be visible to a named owner, with a second attempt through a different channel. Contact information should be confirmed at every visit, and young adults who move often may need text, portal and pharmacy reminders rather than mailed letters. Outreach that stops after one failed call is not a recall system.

Practice-level improvement work shows both promise and limits. In a stepped-wedge trial in rural Oregon primary care, 36 of 45 clinics (80%) completed 18 months of practice facilitation.^[12] Most clinics focused on series completion (72%), using strategies such as reminder recall, staff education and workflow adaptation.^[12] Vaccination rates rose over time, with completion increasing 1.4% per quarter, but there was no additional effect attributable to the intervention.^[12]

The same trial found that quality improvement capacity improved significantly, with the largest gains in care coordination.^[12] The authors pointed to pandemic disruptions and variable implementation, and called for higher-intensity external support for busy, under-resourced practices.^[12] For executives, the lesson is that facilitation alone may not be enough without dedicated staff time and data support. Measurement also needs care, since rates that rise everywhere can hide whether a specific change helped.

Follow-up after screening is the other end of the continuum. Because high-grade disease can be present despite a reassuring examination, abnormal results need owned tracking until a diagnostic answer or documented surveillance plan exists.^[14] Results that fall between gynecology, primary care and pathology are where that ownership most often lapses. A weekly list of open abnormal results, reviewed by a named clinical lead, is a simple and auditable control. Patients who move between systems need an explicit transfer of that responsibility.

Figure 3

Why the pathway breaks

People

Clinicians do not give a clear, consistent recommendation
Dental and pharmacy teams unsure their referrals will be completed
No named coordinator for reminder-recall

Process

Next dose not scheduled at the current visit
Failed contacts not retried through another channel
Abnormal results not tracked to a diagnostic answer

Technology

Patients cannot see their own vaccination status
Outdated contact information
No shared dose records with school partners

Environment

Rural distance and limited clinic capacity
Transient living situations among young adults
Pandemic and other service disruptions

Policy

No school partnership or consent agreement
Unclear cost messaging for families
Recommendations limited to a narrow age window

Measurement

Initiation tracked but completion not
Results not stratified by age, language and identity
Campaign reach reported instead of protection

Unranked qualitative cause-and-effect diagram for the outcome in the box: Eligible people do not start or complete HPV vaccination, or do not complete screening follow-up after an abnormal result Causes are assembled from the cited literature [1], [2], [3], [4], [10], [12], [13], [14], [15]; categories are not weighted and their order carries no meaning.

Data note. Qualitative; no frequencies are implied.

Limitation. Causes drawn from published studies may not all apply locally; validate them with frontline teams.

Figure data (6 rows)

Figure 3 data: Why the pathway breaks
Category	Causes drawn from the cited literature
People	Clinicians do not give a clear, consistent recommendation; Dental and pharmacy teams unsure their referrals will be completed; No named coordinator for reminder-recall
Process	Next dose not scheduled at the current visit; Failed contacts not retried through another channel; Abnormal results not tracked to a diagnostic answer
Technology	Patients cannot see their own vaccination status; Outdated contact information; No shared dose records with school partners
Environment	Rural distance and limited clinic capacity; Transient living situations among young adults; Pandemic and other service disruptions
Policy	No school partnership or consent agreement; Unclear cost messaging for families; Recommendations limited to a narrow age window
Measurement	Initiation tracked but completion not; Results not stratified by age, language and identity; Campaign reach reported instead of protection

Access

Bringing vaccination and screening to where people already are

Schools are the most consistent access point in the evidence. In a cluster-randomized trial in Colombia, post-intervention vaccination was 52.4% among girls in schools that received a behavioral program and 28.6% in control schools.^[8] The program combined a workshop for girls, a letter, an open chat, multimedia messages and parental reminders.^[8] It was delivered with existing program resources, which the authors said supports use in similar school settings.^[8]

Health systems in the United States rarely run school programs alone, but they can partner with districts, school nurses and school-based health centers. The eight-country analysis linked the strongest coverage to school delivery supported by nursing and school health workforces.^[1] Partnership agreements should specify consent processes, data sharing for dose records and who schedules the next dose. They should also define how families are told about results and next steps when vaccination happens outside the clinic.

Age of the first recommendation is also an access decision. A national survey of 2,272 parents of children aged 9 to 10 found that parents who follow provider guidance on vaccination age had greater intention to vaccinate at ages 9 to 10.^[3] The authors suggested that an expanded age range of 9 to 12 may create opportunities for repeated provider recommendation.^[3] More eligible visits mean more chances to start the series. The same authors noted that moving the routine age alone may not increase overall vaccination rates.^[3]

Other clinical settings can widen the front door. Among dental hygienists attending a continuing education course, 15% recommended the HPV vaccine to patients and 16% provided vaccine education.^[13] Many (59%) did not believe patients would follow through on referrals to primary care.^[13] A referral that the sending team expects to fail is a broken handoff, and it signals the need for a direct scheduling route.

Screening access is changing as well. A review of 824 research articles on HPV self-sampling found that the field has shifted toward programmatic implementation in higher-risk populations, with growing emphasis on equity and digital support.^[5] Self-collection offers a route for people who avoid or cannot reach clinic-based screening, provided results and follow-up stay connected to an owner. A self-collection kit that is returned but never followed up simply moves the gap to a different place. Kit tracking, result delivery and diagnostic scheduling need the same ownership as clinic-based screening.

System route

Connect information, prevention, screening, and follow-up.

The route should be inclusive of all people affected by HPV and aligned with current local clinical guidance.

The route at a glance

Inform without stigma
Offer prevention
Screen appropriately
Close the loop

Inform without stigma
Use accurate language about transmission, cancer risk, vaccination, and screening without moral judgment.
Offer prevention
Build age-appropriate vaccination assessment and recommendation into routine encounters and outreach.
Screen appropriately
Apply current screening guidance to eligible populations and document exceptions or deferrals.
Close the loop
Communicate results, arrange diagnostic follow-up, and maintain recall under named ownership.

Reliability rule: A campaign impression is not a completed prevention pathway. Measure vaccination and screening completion, not message reach alone.

Figure 2

The system route as one flow

The five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.

Data note. Shows sequence and handoffs only; it carries no counts or rates.

Limitation. Local processes may add, merge or reorder stages under organizational policy.

Figure data (4 rows)

Figure 2 data: The system route as one flow
Stage	What the stage requires
Inform without stigma	Use accurate language about transmission, cancer risk, vaccination, and screening without moral judgment.
Offer prevention	Build age-appropriate vaccination assessment and recommendation into routine encounters and outreach.
Screen appropriately	Apply current screening guidance to eligible populations and document exceptions or deferrals.
Close the loop	Communicate results, arrange diagnostic follow-up, and maintain recall under named ownership.

Equity and trust

Equity, stigma and trust in HPV prevention

Gaps in HPV prevention follow familiar fault lines of geography, language, age and identity. Rural adolescents in the United States are under-vaccinated, which motivated the Oregon primary care trial.^[12] In the border county program, young adults completed the series less often than younger participants, while people born in Mexico were more likely to complete it.^[15] Equity work therefore requires stratified data, not assumptions about which group is behind. Data should include age, language, geography, payer and, where patients choose to share it, sexual orientation and gender identity.

Sexual and gender minority populations face specific HPV-related disparities, including higher rates of healthcare discrimination.^[6] In a 2024 national survey of 483 U.S. primary care clinicians responding to clinical vignettes, 59–69% reported they would always recommend the HPV vaccine.^[6] Recommendations differed very little by patient sex, sexual orientation or gender identity.^[6] Self-reported intent is encouraging, but leaders still need actual recommendation and completion data by population. Clinician self-reports in surveys can overstate everyday practice, so audit data from visits matter.

Stigma can keep HPV out of routine conversation. HPV prevention messages work best when framed as cancer prevention offered to everyone eligible, rather than as a judgment about behavior. Systems can reinforce that framing through standard language in visit templates, patient portals and school materials, so that no family feels singled out. Staff training should include how to answer common questions without implying blame, and how to protect privacy when results are discussed.

Cost and clarity are equity issues too. In Tonga, knowing that the vaccine was free was the strongest predictor of uptake.^[10] The Nigerian review identified vaccine cost and limited availability among the barriers to uptake.^[11] In the United States, families may not know what their coverage includes, so plain statements about cost at the point of recommendation can remove a quiet barrier.

Research capacity is unevenly distributed as well. The self-sampling review found that research remains geographically concentrated, with the United States and Australia as major contributors.^[5] Its authors called for partnerships led by stakeholders in high-burden settings.^[5] Within a single health system, the same principle applies: communities with the lowest coverage should help design the fix. Community advisory input on outreach materials and clinic hours is a low-cost way to start.

A nurse practitioner talks with a woman in her forties about cervical screening in a health center exam room. — Illustrative image. School-based delivery supported by nursing and school health workforces achieved the highest and most equitable coverage across eight countries.^[1]

Human infrastructure

Nurses, clinicians and the teams that carry prevention

Nurses sit at the center of effective HPV programs. The eight-country analysis concluded that vaccination outcomes are shaped by governance structures, implementation capacity, nursing workforce infrastructure and public trust.^[1] Its authors called for investment in nursing-led outreach and school-based models.^[1] For health systems, that means school nurse partnerships and nurse-led standing orders deserve budget and leadership attention.

Clinicians need training that fits their schedules. In interviews used to develop a provider-focused training, 15 U.S. primary care providers gave favorable feedback on the education materials.^[2] They asked for flexibility in format and timing because of busy schedules, and suggested incentives to encourage participation.^[2] They had mixed feelings about role-play and recommended clear language.^[2] Brief, repeated training that respects clinic time is more likely to reach busy teams than a single long session. Training completion and recommendation rates can then be reviewed together.

Training should also address clinicians’ own beliefs about follow-through. The dental hygienists who doubted that patients would complete primary care referrals also felt that patients would be more receptive if dentists made the referral (39% versus 22%).^[13] Team roles, scripts and direct scheduling can reduce that uncertainty and make every member of the dental or clinical team part of the route. A dental office that can book a vaccine visit directly removes the step that hygienists expected to fail.

Clinician type affects recommendation behavior. In the national vignette survey, advanced practice providers were more likely than physicians to recommend the HPV vaccine.^[6] That finding supports using the full care team, including nurses, pharmacists and advanced practice providers, rather than relying on physicians alone. Standing orders and protocols that allow nurses and pharmacists to recommend and administer the vaccine extend the number of moments when a recommendation can happen.

Improvement work requires people as well as tools. The rural trial measured gains in quality improvement capacity, with care coordination showing the largest improvement.^[12] Its authors called for higher-intensity external support for busy and under-resourced practices and for engaging community partners outside clinics.^[12] Executives should fund a named coordinator for reminder-recall and abnormal result tracking rather than adding the work to already full roles.

Operating dashboard

Measure opportunity, completion, and diagnostic closure.

Stratify by age, geography, race and ethnicity, language, payer, gender identity, and care setting where lawful and appropriate.

Four operating signals

Vaccination opportunitySeries statusScreening completionAbnormal result closure

Each signal pairs an executive question with one candidate local measure, set out below.

Vaccination opportunity

Track eligible encounters with a documented offer and disposition.

Measure: Eligible encounters with completed assessment

Series status

Follow people who need additional doses under current guidance.

Measure: Eligible population up to date

Screening completion

Measure completed screening among eligible patients rather than orders alone.

Measure: Current screening completion rate

Abnormal result closure

Track abnormal results to diagnostic resolution or documented surveillance.

Measure: Results closed within standard

Figure 4

The operating system behind the dashboard

The four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.

Data note. Structural diagram; no measured values.

Limitation. Owners are candidates to be confirmed locally.

Figure data (4 rows)

Figure 4 data: The operating system behind the dashboard
Operating signal	Candidate owner
Vaccination opportunity	Population health
Series status	Primary care and gynecology
Screening completion	Diagnostic services
Abnormal result closure	Patient experience

Handoff workflow

Make every prevention handoff confidential and closed loop.

Patients should not have to translate between vaccine, screening, and specialty systems.

How responsibility moves

Lane 1Primary care to vaccination3 steps

Lane 2Screening to diagnostics3 steps

Lane 3Diagnostics to ongoing care3 steps

Lane

Primary care to vaccination

Assess eligibility and prior doses.
Give a clear recommendation and answer questions.
Schedule or administer the next dose.

Lane

Screening to diagnostics

Communicate the result privately.
Send complete records with urgency.
Confirm acceptance and next contact.

Lane

Diagnostics to ongoing care

Explain findings and options.
Assign treatment or surveillance ownership.
Restore recall if care moves between systems.

Protect confidentiality and use language that normalizes HPV as a common infection while respecting each person’s questions and choices.

Executive scorecard

Ask where one less worry becomes one missed step.

Review prevention and follow-up together while keeping vaccination and screening measures clinically distinct.

Who reviews what

Population health
Primary care and gynecology
Diagnostic services
Patient experience

Candidate owners named in the scorecard, confirmed locally.

Use stable definitions and stratify results by site, population, and service line when appropriate.
Signal	Executive question	Accountable owner	Review cadence
Vaccination	Which eligible groups have the largest completion gaps?	Population health	Monthly
Screening	Are eligible patients current under approved guidance?	Primary care and gynecology	Monthly
Closure	How many abnormal results remain unresolved?	Diagnostic services	Weekly
Experience	Do patients report respectful, understandable communication?	Patient experience	Quarterly

Figure 5

Control points for an HPV prevention operating system

Figure 5: Control points for an HPV prevention operating system
Control point	Risk if missing	Owner	Evidence of control
Standard recommendation at every eligible visit	Trust is not converted into vaccination	Chief medical officer with primary care lead	Share of eligible visits with a documented recommendation
Next dose scheduled before the patient leaves	Series stalls after the first dose	Clinic operations manager	Share of first doses with a scheduled second dose
Multi-channel reminder-recall with retry	Failure to contact ends the series	Population health coordinator	Completion rate and failed-contact follow-up reported monthly
School and community partnership agreements	Adolescents reached only when they visit a clinic	Community health director	Signed agreements with consent and data-sharing terms
Direct scheduling from dental and pharmacy settings	Referrals to primary care are not completed	Ambulatory access lead	Referral-to-dose completion tracked
Owned abnormal result tracking	High-grade disease missed between services	Women’s health and pathology leads	Open abnormal results reviewed weekly until closure
Stratified coverage dashboard	Equity gaps stay hidden in averages	Quality and analytics lead	Coverage and completion reported by age, language, geography and identity

Control points derived from the cited evidence [1], [4], [10], [12], [13], [14], [15] and this brief’s executive guidance.

Data note. Each row is a control to verify, not a measured result.

Limitation. Owners and evidence of control must follow local policy and applicable requirements.

Public communication

Clear, consistent and stigma-free public communication

The strongest message is a clear recommendation from a trusted clinician. In the university survey, 59% of students reported at least one HPV vaccine dose, and 17.7% were unsure of their vaccination status.^[4] Students whose provider recommended the vaccine were far more likely to be vaccinated.^[4] Communication plans should start with what clinicians say in the room, then extend outward. A short shared script, tested with patients, helps every team member deliver the same message.

Uncertainty about one’s own status is a communication failure the system can address. Patient portals, school records and pharmacy data can tell people whether they have started or completed the series. A simple status message with a scheduling link turns awareness into action. For young adults who aged out of pediatric care, that message may be the first reminder they have received in years.

Messages to parents should be tailored to their experience. In the national parent survey, parents with an HPV-vaccinated older child reported the highest perceived benefits and lowest perceived barriers to vaccinating at ages 9 to 10.^[3] The authors recommended communication strategies personalized to parents’ prior vaccine decisions.^[3] A family that has vaccinated before needs a reminder; a family that declined before needs a conversation. Clinicians should have time and permission to return to the topic at later visits without pressure.

Community voices extend reach where clinicians cannot. The Tonga study recommended strategic engagement of community and faith leaders and institutionalizing school-based consent processes.^[10] In Colombia, parental reminders and multimedia messages were part of the school program that raised vaccination.^[8] U.S. health systems can apply the same logic through faith-based, school and community partners who help shape and deliver the message. Materials should be available in the languages families use and reviewed by those partners before release.

Public interest can be monitored as well as created. In the European study, online search interest in the HPV vaccine correlated strongly with coverage (r = 0.89).^[7] Leaders should pair any campaign with completion measures, so that reach is never reported as if it were protection. Public reports should state vaccination starts, completions and screening follow-up separately, with definitions. Sharing progress with schools and community partners keeps them invested in the next cycle.

A boy walks with friends toward the school door along a path lined with early crocuses. — Illustrative image. Failure to contact was the most common barrier to HPV vaccine series completion in one border county program.^[15]

90-day plan

Close one HPV prevention gap in 90 days.

Choose one population with measurable vaccination, screening, or follow-up inequity.

Ninety days, three moves

Days 1–30Find the missed steps
Days 31–60Test a connected intervention
Days 61–90Build durable prevention

Days 1–30

Find the missed steps

Map the end-to-end pathway.
Baseline opportunity and completion rates.
Listen to patients and frontline teams.

Days 31–60

Test a connected intervention

Standardize one recommendation workflow.
Add confidential reminder and recall.
Review unresolved abnormal results weekly.

Days 61–90

Build durable prevention

Compare results across groups.
Embed roles and escalation in standard work.
Set the next target with community partners.

Figure 6

The 90-day plan on one timeline

The 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.

Data note. Time boxes are a management framework, not a clinical timeline.

Limitation. Durations are uniform 30-day windows; real tasks may span windows.

Figure data (9 rows)

Figure 6 data: The 90-day plan on one timeline
Window	Action
Days 1–30	Map the end-to-end pathway.
Days 1–30	Baseline opportunity and completion rates.
Days 1–30	Listen to patients and frontline teams.
Days 31–60	Standardize one recommendation workflow.
Days 31–60	Add confidential reminder and recall.
Days 31–60	Review unresolved abnormal results weekly.
Days 61–90	Compare results across groups.
Days 61–90	Embed roles and escalation in standard work.
Days 61–90	Set the next target with community partners.

Prevention works only when people can reach it.

International HPV Awareness Day 2026 is an opportunity to turn trusted information into reliable vaccination, screening, and follow-up.

Executive action
Fund one 90-day HPV pathway pilot that measures completed prevention and diagnostic closure across patient groups.

Operational readiness verification

Make the observance visible in everyday operations.

International HPV Awareness Day becomes meaningful when people receive accurate prevention information and move through recommended services and abnormal-result resolution without stigma. The weak version is a message without an operating change. The stronger version defines what teams should see, who owns each transition, how exceptions escalate, and how leaders know that the pathway actually closed.

The principal failure mode is that HPV prevention, vaccination, screening, abnormal-result follow-up, and cancer care can be separated by age, setting, and ownership. Leaders should test the route with recent cases, frontline staff, patients or community partners, and the teams that receive the next handoff. That review should distinguish a written policy from reliable execution under real workload, staffing, access, and communication conditions.